newsfilter
← Latest News
PR Newswire·

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA

YS

GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,